Lu-177 Dotatoc for neuroendocrine and other sst2-positive cancers
Part of Cancer clinical trials.
This trial tests a type of radiation therapy called Lu-177 Dotatoc (PRRT) for people with neuroendocrine tumors or other cancers that have high levels of a specific protein (sst2). It may be an option when standard treatments stop working or aren't available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your tumor must show high uptake on a 68Ga PET scan (Krenning grade 3 or 4).
- Your disease must have gotten worse in the past 12 months despite other treatments.
- You must be in fairly good health (ECOG score 0 or 1).
- Your blood counts, liver, and kidney function must be adequate as checked by labs.
- If you can become pregnant or have a partner who can, you must use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies Lu-177 DOTATATE (Lutathera), a targeted radiation medicine, for tumors that cannot be safely removed with surgery. It aims to shrink or control pheochromocytoma/paraganglioma that is showing recent growth and has a specific target signal on a special PET scan.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This trial tests a new radioactive drug, Terbium-161 DOTATATE, for people with advanced neuroendocrine tumors that have stopped responding to a similar treatment called Lu-177 DOTATATE. It aims to see if this new drug is safe and can help shrink tumors.
This study tests whether combining Lu-177 dotatate (a targeted radiation treatment) with olaparib (a targeted pill) can shrink or slow growth of inoperable gastroenteropancreatic neuroendocrine tumors. It’s designed for tumors that show the right “targets” on a special scan and that have started to progress despite standard care.
This trial tests a radioactive drug called Lutathera for people with neuroendocrine tumors that are not in the stomach or intestines and can't be removed by surgery. The drug targets a specific receptor on the tumor cells to deliver radiation directly, which may help slow or shrink the cancer.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.